

**European Task Force on Atopic Dermatitis / EADV Eczema Task Force
12.10.2009****MINUTES OF THE BERLIN MEETING
October 7, 2009**

Present: M. Ambonati (Ducray Aderma) - T. Bieber (Bonn) - U. Darsow (Munich TU) - Deleuran (Aarhus) – C. Gelmetti (Milano) - U. Gieler (Gießen) – A. Holm (Aarhus) – L. Korhonen (Tampere) – B. Kunz (Hamburg) – A. Oranje (Rotterdam) - L. De Raeye (Brussels) – D. Simon (Bern) – J.F. Stalder (Nantes) - A. Svensson (Malmö) – A. Taieb (Bordeaux) – C. Vestergaard (Aarhus) - N. Wiel (Quanta) - A. Wollenberg (Munich LMU)

The meeting was held at the Hotel Concorde Berlin. The following dinner was again generously sponsored by Ducray/Aderma.

1. **Patient-oriented SCORAD:** Before the ETFAD annual meeting, the meeting of the PO-SCORAD study group was held. The study will enter into the analysis phase after November 2009. At the start of the ETFAD meeting, the publication strategy of the corresponding PO-SCORAD data was discussed. Probably by June 2010 a publication on the primary end points will be compiled. A writing committee was

proposed and will be organized by J.F. Stalder and A. Taieb. U. Gieler suggests not to publish preliminary data. A. Holm points to problems correlating the subjective scales of SCORAD and PO-SCORAD. M. Ambonati mentions interesting results of a clinical study using both SCORAD and PO-SCORAD – patients rated less therapy success compared to their doctors. Further information on the progress with PO-SCORAD will be circulated by the organizers of the study.

A. Holm wants to start a study using PO-SCORAD. J.F. Stalder states that no limitation to use this new instrument applies except giving credentials to Ducray/Pierre-Fabre for their support to develop this instrument. This was already unanimously accepted during the PO-SCORAD meeting in Paris 2008. A. Taieb reminds that ETFAD should also be mentioned in PO-SCORAD activities. J.F. Stalder additionally mentions that PO-SCORAD will perhaps be used in a new ISAAC study. PO-SCORAD picture material can be taken from the OPENED website. However, high-quality pictures are not yet available but may be acquired by a direct request to the AD FOUNDATION (Fondation Dermatite Atopique).

2. **OPENED project (J.F. Stalder):** The website (www.opened-dermatology.com) is used with increasing frequency and success. Correspondingly J.F. Stalder announced a call for appointment from an Irish colleague for educational data with the website. Patient-oriented talks or presentations can be collected on this website, too. An impressive demonstration of the functionality of the website was given online during the meeting. Presentations can be found under „worldwide experiences/interviews“ on the OPENED site, including a presentation on the PO-SCORAD. J.F. Stalder points to the open character of this website and asks for news and remarks that can be put by his webmaster. The whole activity is funded by a grant of the AD Foundation.
3. **Finalized new ETFAD position paper on eczema diagnosis and treatment:** U. Darsow thanks all authors and contributors of this ETFAD activity. The paper is now in publication and will also be available on an open access basis via the EADV website. C. Gelmetti points to the fact that the treatment figure of the position paper applies only to adults and announces further activities for a similar figure for the treatment of children. U. Darsow reports on the progress of a planned collaboration with EDF (European Dermatology Forum) for a new guideline on AD treatment based on EBM measures. For this activity, A. Wollenberg proposes national guideline groups to be included.
4. **Discussion and proposals of future projects for the ETFAD:** C. Gelmetti proposes a consensus paper on „what not to do in AD“ with a collection and summary of studies in this field. A corresponding writing group can be organized by C. Gelmetti.
5. **ETFAD symposium:** The next ETFAD symposium will be the 10th symposium and highlights the 20th anniversary of ETFAD. If abstracts are to be included in the abstract CD ROM of the Göteborg congress, a call has to be made in March/April (U. Darsow). Efforts for integrating the ETFAD activities in the main programme of the EADV congress are ongoing. A. Taieb suggests another format for the symposium including reviews as well as original data.
6. **Discussion:** For future studies, T. Bieber suggests to make better characterizations of terms frequently used for clinical scoring systems, example: „How to define flare“. Probably a workshop on nomenclature is necessary. C. Gelmetti starts a discussion on new better drawings for the established SCORAD system. A. Wollenberg and U. Gieler point to problems with the previous evidence of SCORAD when the picture material is changed.

7. **Next meeting planning:** The next regular ETFAD meeting is planned at the venue of the EADV congress in Göteborg 2010. Wednesday, October 6 seems suitable, time and location to be announced. In addition, plans for the 10th ETFAD symposium there will be communicated in time.

Best regards,

Ulf Darsow

Dept. of Dermatology and Allergy Biederstein
Technical University Munich
Biedersteiner Str. 29
D-80802 München
Tel ++49 89 4140 3463
Fax ++49 89 4140 3171
e-mail ulf.darsow@lrz.tum.de